Exalenz Bioscience Adds Johns Hopkins Health Care & Surgery Center to Its Expanding Roster of U.S. Customers

Exalenz Bioscience, Inc., a provider of breath testing equipment for the diagnosis
and management of digestive system and liver conditions, today announced the installation of its
BreathID® System for Helicobacter pylori (H. pylori) detection at the Johns Hopkins Health Care &
Surgery Center at Green Spring Station.

The BreathID® Urea Breath Test System offers a highly accurate, rapid, point-of-care assessment of H.
pylori, which infects approximately 25 to 30 percent of the United States population. BreathID delivers
results in about 10 minutes – about half the time of competitive devices – making it well suited for pointof-
care testing.

H. pylori, a bacterium that can reside in the stomach and small intestine, has been demonstrated to
contribute to a variety of conditions, ranging from relatively common symptoms such as dyspepsia and
abdominal pain to more severe conditions, including gastritis, ulcers and, in some cases, gastric cancer.
Conclusively eradicating H. pylori through treatment depends on an accurate diagnosis of active H. pylori
infection.

Urea breath tests (UBT) are the non-invasive mode of choice for diagnosing H. pylori. According to the
American College of Gastroenterology’s (ACG) 2007 guidelines, the tests most widely used by U.S.
physicians (blood antibody tests) are “no better than a coin toss in predicting active infection.” UBT – and
the BreathID System – have been proven to accurately and reliably detect active infection, and their use
is supported by the ACG clinical guidelines.

“We are pleased that Johns Hopkins has chosen to utilize the BreathID System as a tool to detect H.
pylori infection in its patients,” said Steven Eitan, Chief Executive Officer at Exalenz Bioscience. “We
continue to see increasing demand for our rapid, point-of-care diagnostic tool, as physicians are looking
for improved accuracy and rapid results.”

About Exalenz Bioscience
Exalenz Bioscience develops and markets medical equipment for breath testing for the purposes of
diagnosis and management of digestive system and liver conditions. The company sells the BreathID®
System together with proprietary disposable test kits. The BreathID® System has been proven effective
for clinical use in identifying the presence of the H. pylori bacteria and is presently undergoing clinical
tests for use in the field of liver function, liver cirrhosis, and digestive disturbances. Exalenz holds
regulatory approvals in Europe and the U.S. for some of the applications and the company is currently in
process of applying for approvals for additional applications.